CERAD test performance and cognitive impairment in Parkinson's disease

Acta Neurologica Scandinavica

Volumn 128, Issue 6, 2013, Pages 409-413

  Karrasch, M ^a   Laatu, S ^b   Martikainen, K ^c   Marttila, R ^d  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c The Finnish Parkinson Association and Foundation   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

CERAD; Clinical dementia rating; Cognitive functions; Dementia; Mild cognitive impairment; Parkinson's disease

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL DEMENTIA RATING; COGNITIVE DEFECT; CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMER DISEASE NEUROCOGNITIVE TEST; CONTROLLED STUDY; DEMENTIA; DISEASE DURATION; EXECUTIVE FUNCTION; FEMALE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY CONSOLIDATION; MENTAL TEST; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE;

CERAD; CLINICAL DEMENTIA RATING; COGNITIVE FUNCTIONS; DEMENTIA; MILD COGNITIVE IMPAIRMENT; PARKINSON'S DISEASE;

ADULT; AGED; AGED, 80 AND OVER; COGNITION DISORDERS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; VERBAL LEARNING; VISUAL PERCEPTION;

EID: 84886640231     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12138     Document Type: Article

References (25)

1. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010;289:18-22.
2. Emre M, Aarsland D, Brown R et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-707.
3. Auyeung M, Tsoi TH, Mok V et al. Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients. J Neurol Neurosurg Psychiatry 2012;83:607-11.
4. Aarsland D, Bronnick K, Williams-Gray C et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062-9.
5. Litvan I, Goldman JG, Tröster AI et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement disorder society task force guidelines. Mov Disord 2012;27:349-56.
6. Litvan I, Aarsland D, Adler CH et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011;26:1814-24.
7. Jellinger K. Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease. J Neural Transm 2012;119:381-2.
8. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010;9:1200-13.
9. Welsh KA, Butters N, Mohs RC et al. The consortium to establish a registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994;44:609-14.
10. Welsh-Bohmer KA, Mohs RC. Neuropsychological assessment of Alzheimer's disease. Neurology 1997;49:S11-3.
11. Welsh KA, Butters N, Hughes JP, Mohs RC, Heyman A. Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1992;49:448-52.
12. Karrasch M, Sinervä E, Grönholm P, Rinne J, Laine M. CERAD test performances in amnestic mild cognitive impairment and Alzheimer's disease. Acta Neurol Scand 2005;111:172-9.
13. Sotaniemi M, Pulliainen V, Hokkanen L et al. CERAD-neuropsychological battery in screening mild Alzheimer's disease. Acta Neurol Scand 2012;125:16-23.
14. Tedrus GMAS, Fonseca LC, Letro GH, Bossoni AS, Samara AB. Dementia and mild cognitive impairment in patients with Parkinson's disease. Arq Neuropsiquiatr 2009;67:423-7.
15. Litvan I, Bhatia KP, Burn DJ et al. Movement Disorders Society Scientific Issues Committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003;18:467-86.
16. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-53.
17. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993;43:2412-4.
18. Fillenbaum GG, Van Belle G, Morris JC et al. Consortium to establish a registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimer Dement 2008;4:96-109.
19. Hänninen T, Pulliainen V, Sotaniemi M et al. Early detection of cognitive changes in memory diseases: new cut-off scores for the Finnish version of CERAD neuropsychological battery. Duodecim 2010;126:2013-21.
20. Sollinger AB, Goldstein FC, Lah JJ, Levey AI, Factor SA. Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics. Parkinsonism Relat Disord 2010;16:177-80.
21. Goldman JG, Litvan I. Mild cognitive impairment in Parkinson's disease. Minerva Med 2011;102:441-59.
22. Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord 2009;24:1103-10.
23. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130:1787-98.
24. Weintraub D, Doshi J, Koka D et al. Neurodegeneration across stages of cognitive decline in Parkinson disease. Arch Neurol 2011;68:1562-8.
25. Di Biasio F, Vanacore N, Fasano A et al. Neuropsychology, neuroimaging or motor phenotype in diagnosis of Parkinson's disease-dementia: which matters most? J Neural Transm 2012;119:597-604.